Outcome Capital Taps AI Pioneer to Guide Healthcare's Digital Future

BOSTON, MA – June 09, 2026 – In a move that signals a significant strategic pivot for the healthcare investment banking sector, Outcome Capital has appointed Dr. David Feygin as a Senior Advisor. While the announcement of a new advisor is typically routine, this particular appointment is a clear bellwether for the industry. By bringing in a leading mind in governed artificial intelligence and digital health, the specialized advisory firm is making an aggressive play to dominate the increasingly complex intersection of life sciences, digital transformation, and AI. The decision illuminates a fundamental shift in where value is being created in healthcare, moving beyond the molecule and the device to the data and the algorithm.

Outcome Capital, a firm known for its strategy-led advisory model, is positioning itself to guide clients through a landscape where digital capabilities are no longer an ancillary benefit but a core driver of competitive advantage and enterprise value. Dr. Feygin's appointment to its Medical Device, Digital Health, and AI practices is less about adding a name to the letterhead and more about embedding deep, operational expertise in a domain that many finance professionals are still struggling to comprehend.

“Digital and AI capabilities are becoming increasingly central to value creation across life sciences and healthcare,” said Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital. “David brings a rare combination of operating leadership, strategic vision and deep sector knowledge across medical technology, digital health, data, analytics and responsible AI.”

The Architect of Governed AI

To understand the gravity of this move, one must first understand Dr. Feygin. His career is a masterclass in navigating the nexus of technology and regulated industries. Before his current entrepreneurial roles, he served as the Chief Digital Health & Data Officer at Boston Scientific, where he was tasked with leading the medical device giant's enterprise-wide digital and data strategy. His experience extends to Becton Dickinson, where his work in strategic innovation helped lay the groundwork for the company’s $12 billion acquisition of CareFusion, a deal that reportedly created $4 billion in shareholder value by integrating information-enabled medication management.

This background alone would make him a valuable asset. However, it is his current work that truly defines his unique value proposition. Dr. Feygin is the CEO and Co-Founder of two ventures: EnPraxis, a “Governed Cognitive Operations” platform, and ShakeIQ, a Redesign Health-backed startup. Both are built on the principle of “Responsible AI,” a concept that is becoming paramount in healthcare.

In high-criticality sectors, the freewheeling, probabilistic nature of many consumer-facing AI models is a non-starter. A mistake in a chatbot's song recommendation is trivial; a mistake in a clinical decision support tool can be catastrophic. “Governed AI” is the solution to this challenge. It refers to AI systems built with guardrails that ensure every output is traceable, auditable, and grounded in verified sources of truth. It is AI designed for environments where trust is not a feature, but the entire foundation. Dr. Feygin’s firm, EnPraxis, is built to provide this layer of trust, enabling compliant and explainable automation in areas like claims processing and compliance monitoring, where accuracy and accountability are non-negotiable.

A Strategic Bet on Digital Convergence

For Outcome Capital, recruiting Dr. Feygin is a direct response to the evolving needs of its clients. Life sciences and healthcare companies are no longer just asking for guidance on traditional M&A or financing. They are grappling with fundamental questions about how to integrate digital tools, leverage vast datasets, and deploy AI to improve outcomes and streamline operations—all while navigating a labyrinth of regulations from bodies like the FDA.

Dr. Ben-Joseph noted that Dr. Feygin’s experience strengthens the firm's ability “to advise clients on navigating market shifts, evaluating strategic alternatives and building differentiated businesses in highly regulated environments.” This is the core of the strategy. As medical device, pharmaceutical, and healthcare service companies become technology companies, they require advisors who speak both languages fluently. An advisor who can dissect a balance sheet is common; one who can also evaluate the architecture of a governed AI platform is a rarity.

Outcome Capital's model, which staffs its teams with former CEOs, clinicians, and scientists, is designed for this type of deep-sector expertise. The addition of Dr. Feygin reinforces this approach, providing the firm with the credibility to not only structure a deal but also to pressure-test the underlying digital strategy of the companies involved. This capability is crucial in a market where a flawed digital product or a non-compliant AI algorithm can become a massive liability post-acquisition.

Riding the Wave of Healthcare's AI Arms Race

The move by Outcome Capital is also a reflection of a broader industry trend. A digital arms race is underway among advisory and investment firms, all vying to capture the explosive growth in the digital health and AI sectors. The COVID-19 pandemic acted as a powerful accelerant, transforming telehealth and remote monitoring from niche services to essential infrastructure. Venture capital has poured into the space, with firms like Redesign Health creating entire venture studios dedicated to building AI-native healthcare companies.

This influx of capital and innovation has created a fertile ground for M&A activity, strategic partnerships, and complex financing rounds. However, valuing these companies and their technology requires a new set of skills. Traditional valuation metrics often fall short when assessing the potential of a proprietary algorithm or a platform's network effects. This is why specialized expertise is now at a premium.

Firms that fail to build this expertise risk being sidelined, unable to provide meaningful advice to a new generation of healthcare innovators or to legacy players attempting to reinvent themselves through digital transformation. By securing a leader like Dr. Feygin, Outcome Capital is not just keeping pace; it is making a bid to lead the pack, betting that the future of healthcare finance will be won by those who best understand its digital present.

From Theory to Practice: The Future of MedTech Engagement

Dr. Feygin’s own words underscore the practical mission behind the high-level strategy. “Healthcare is at a pivotal point where the responsible application of AI can materially improve patient access, outcomes and operational performance,” he stated. He expressed excitement to “help clients translate digital and AI innovation into sustainable growth, stronger strategic positioning and meaningful value creation.”

His startup, ShakeIQ, provides a tangible example of this translation in action. The company is developing an AI-driven platform to transform how medical device companies engage with physicians. By providing sales representatives with governed, verified clinical and business knowledge on a mobile-first platform, ShakeIQ aims to expand patient access to life-changing technologies and reduce the administrative burden on providers. It is the real-world application of the governed AI principles championed by EnPraxis, aimed directly at solving a persistent and costly problem in the MedTech industry.

This blend of hands-on entrepreneurial experience and high-level strategic vision is precisely what makes this appointment so compelling. It provides Outcome Capital with not just a theorist, but a practitioner who is actively building the future he is advising on. For clients, this means access to insights that are not just academically sound, but battle-tested in the competitive marketplace.